| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -26,450 | -40,950 | -28,800 | -37,150 | -29,770 |
| Net Income Growth | +35.41% | -42.19% | +22.48% | -24.79% | -44.94% |
Acumen Pharmaceuticals Inc
(ABOS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va.
Fiscal Year End Date: 12/31